Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Julphar
Cipla
Moodys
UBS
Dow
Accenture
Deloitte

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,106,183

« Back to Dashboard

Summary for Patent: 8,106,183
Title:Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs
Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A.sub.2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Inventor(s): Zablocki; Jeff (Mountain View, CA), Elzein; Elfaith (Fremont, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/765,623
Patent Claim Types:
see list of patent claims
Compound; Use; Process;

Drugs Protected by US Patent 8,106,183

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,106,183

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,988 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
9,085,601 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
7,671,192 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
8,524,883 Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,106,183

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1989214 ➤ Try a Free Trial
European Patent Office 2581381 ➤ Try a Free Trial
Spain 2593028 ➤ Try a Free Trial
Israel 193153 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
QuintilesIMS
Harvard Business School
Chinese Patent Office
Express Scripts
Cantor Fitzgerald
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.